Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tesaro

- PMLiVE

GSK eyes first-line use for leukaemia drug Arzerra

Positive phase III trial results back regulatory filings for earlier use

- PMLiVE

FDA clears two GSK melanoma drugs

Tafinlar and Mekinist approved in the US along with companion diagnostic

- PMLiVE

GSK boost vaccines capabilities with €250m Okairos purchase

Acquires novel platform technology and several early stage assets

- PMLiVE

VCCP Health wins Mundipharma’s new product launch business

Agency hired to drive new product launches across Europe

- PMLiVE

GSK awarded $200m by US government for antibiotic research

Follows state-supported schemes in Europe to combat resistance to antibiotics

- PMLiVE

Roche repeats cancer drugs warning as Avastin faces another NICE rejection

Concerns about future of Cancer Drugs Fund

Payer focus in the personalised world of oncology and orphan diseases

Personalised medicine is transforming disease understanding and many traditional diagnoses may be fundamentally revised based on the new scientific understanding

Bayer symbol

FDA clears Bayer/ Algeta’s prostate cancer radiotherapy

Approval for Xofigo comes three months ahead of schedule

- PMLiVE

FDA expands use of Roche/ Astellas’ Tarceva in lung cancer patients

New indication approved alongside companion diagnostic to detect gene mutation

GSK partners with Save the Children to tackle child mortality in Africa

Firm will develop and distribute medicines in some of the world’s poorest countries 

- PMLiVE

Elan buys into GSK-partnered Theravance programmes for $1bn

Takes a royalty interest in four respiratory drugs

- PMLiVE

GSK wins US approval for Seretide successor Breo Ellipta

FDA gives green light to COPD combination

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links